The "15th Five-Year Plan for the Development of the Pharmaceutical Industry" Is Released: The Annual Average Growth Rate of the Innovative Drug Industry Scale Will Exceed 20%

On September 18, the Ministry of Industry and Information Technology, the National Development and Reform Commission, and eight other departments jointly issued the "15th Five-Year Plan for the Development of the Pharmaceutical Industry." The Plan sets development goals through 2030: biomedical R&D and application will remain firmly in the world's front ranks, the effectiveness of innovation-driven development will be fully unleashed, systematic breakthroughs will be achieved in key core technologies in priority fields, and the biomedical industry will accelerate its rise as a national emerging pillar industry. At the same time, the Plan sets out 10 anticipated indicators covering industrial scale and efficiency, innovative development, enterprise cultivation, and cluster development, including the operating revenue of pharmaceutical industrial enterprises above designated size, R&D investment intensity, the number of innovative drugs and medical devices approved for market launch, and the cultivation of leading enterprises and hundred-billion-yuan parks. Specifically, these include: industrial scale and efficiency will improve steadily, with the operating revenue of pharmaceutical industrial enterprises above designated size exceeding 3.5 trillion yuan, the scale of the innovative drug industry growing at an average annual rate of more than 20%, and the number of products with annual global sales exceeding US$1 billion reaching more than 5; innovative development will continue to make breakthroughs, with the average R&D investment intensity of listed pharmaceutical industrial enterprises reaching more than 10% annually, the number of new drug R&D pipelines entering first-in-human clinical trials and the number of innovative drugs approved for market launch ranking among the world's front ranks, the proportion of first-in-class (FIC) drugs accounting for more than 25% globally, and the number of Innovative Medical Management devices approved for market launch reaching more than 200; enterprise cultivation and cluster development will reach a new level, with the number of pharmaceutical industrial enterprises with annual operating revenue exceeding 10 billion yuan reaching 50, and the number of hundred-billion-yuan pharmaceutical industrial parks reaching 20. This article was compiled from the official website of the "Ministry of Industry and Information Technology," edited by Jiang Yuanhua for GMTEight.